Investing.com - Avadel Pharma reported on Monday first quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-0.23 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.3057 on revenue of $0.00.
Avadel Pharma shares are up 53.73% from the beginning of the year, still down 22.03% from its 52 week high of $10.32 set on March 15. They are outperforming the S&P 500 which is up 11.53% from the start of the year.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Pfizer had beat expectations on May 4 with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7759 on revenue of $13.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar